Important caveat: injectable and IV NAD+ are not FDA-approved (nor approved by any major regulator) for energy, metabolic or longevity uses, and their safety and efficacy for these marketed uses are not established
Benefits of Topical Administration Direct Skin Benefits: Targets signs of aging including wrinkles, fine lines, and loss of elasticity
NICE has issued technology appraisals for semaglutide 2.4 mg (Wegovy) for weight management (TA875) and for tirzepatide (Mounjaro) for managing overweight and obesity , each with defined eligibility criteria
Possible side effects are pain, redness, or itching at the site of the injection, mild diarrhea, acne, muscle cramps and irregular heartbeat
Reconstitution and handling Tirzepatide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting